Literature DB >> 15828066

Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC.

A Arzuaga1, A Isla, A R Gascón, J Maynar, A Martín, M A Solinís, D Toral, J L Pedraz.   

Abstract

Simple and reproducible HPLC methods for the determination of piperacillin and tazobactam have been developed and a complete stability study carried out. The method for piperacillin plasma samples consisted of protein precipitation with methanol using penicillin G as internal standard. No sample preparation was needed for ultrafiltrate samples. Tazobactam sample preparation involved protein precipitation with acetonitrile and the removal of lipids with dichloromethane. Piperacillin separation was performed on a microBondapack C(18) column (300 x 3.9, 10 microm) and tazobactam on a Novapack C(18) column (150 x 3.9, 4 microm) with UV detection set at 229 and 225 nm, respectively. The mobile phase consisted of phosphate buffer-acetonitrile, delivered at 1.5 mL[sol ]min. Calibration curves determination coefficients were >or=0.999 and response factors CV% < 5%. Intra- and inter-assay precision and accuracy of the quality control and limit of quantification were satisfactory. Plasma and ultrafiltrate samples were stable at -20 and -80 degrees C for 2 months and after three freeze-thaw cycles. In the chromatographic rack, tazobactam ultrafiltrate samples were stable for 24 h and plasma samples for 12 h, piperacillin ultrafiltrate samples for 8 h, but plasma samples for only 4 h. Storage of piperacillin samples at 4 degrees C until analysis is recommended. Piperacillin was stable in the presence of tazobactam. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828066     DOI: 10.1002/bmc.482

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  5 in total

1.  Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Authors:  Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

2.  Population pharmacokinetic analysis of piperacillin in burn patients.

Authors:  Sangil Jeon; Seunghoon Han; Jongtae Lee; Taegon Hong; Jeongki Paek; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens.

Authors:  Sylvia M Verhoven; Joseph J Groszek; William H Fissell; Adam Seegmiller; Jennifer Colby; Pratish Patel; Alain Verstraete; Matthew Shotwell
Journal:  Clin Chim Acta       Date:  2018-03-26       Impact factor: 3.786

4.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Population pharmacokinetics of piperacillin using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniel K Benjamin; Ashley Ross; Laura P James; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniele Ouellet
Journal:  Ther Drug Monit       Date:  2012-06       Impact factor: 3.681

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.